Clinical trial
IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT05081609 is registered in ClinicalTrials.gov with Ascendis Pharma Oncology Division A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
- Lead sponsor
- Ascendis Pharma Oncology Division A/S
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- January 11, 2022
- Completion date
- August 31, 2029
- Enrollment
- 320 (actual)
- Sites
- 68
Conditions
As the registry lists them; a condition with its own page is linked.
2l+ cervical cancer, advanced solid tumor, locally advanced solid tumor, metastatic solid tumor, neoadjuvant melanoma, neoadjuvant non-small cell lung cancer, platinum-resistant ovarian cancer, post anti-pd-(l)1 non-small cell lung cancer, post anti-pd-(l)1 small cell lung cancer, post anti-pd-1 melanoma, second or third line (2l/3l) cervical cancer, third line or later (3l+) her2+ breast cancer, third-line or later (3l+) platinum-resistant ovarian cancer (proc)